To confirm that these findings were not confined to this leukemia, given the heterogeneous nature of AML, we sought to demonstrate that the drug combination could also elicit improved killing in a distinct AML mouse model, namely the MLL-AF9 mouse model. This evidence concerns the gene KMT2A and leukemia.